Medical Oncology

Andrew John Armstrong, MD

Professor of Medicine
Associate Professor in Pharmacology and Cancer Biology
Associate Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-8797
Email address andrew.armstrong@duke.edu

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

In Their Words

Education and Training

  • Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine, 2003 - 2006
  • Internship/Residency, General Internal Medicine, University of Pennsylvania School of Medicine, 2000 - 2003
  • M.Sc., Johns Hopkins University, 2008
  • M.D., University of Virginia School of Medicine, 2000
  • B.S.E., Duke University, 1996

Grants

Publications

Armstrong, AJ, Halabi, S, Luo, J, Nanus, DM, Giannakakou, P, Szmulewitz, RZ, Danila, DC, Healy, P, Anand, M, Rothwell, CJ, Rasmussen, J, Thornburg, B, Berry, WR, Wilder, RS, Lu, C, Chen, Y, Silberstein, JL, Kemeny, G, Galletti, G, Somarelli, JA, Gupta, S, Gregory, SG, Scher, HI, Dittamore, R, Tagawa, ST, Antonarakis, ES, and George, DJ. "Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology (March 13, 2019): JCO1801731-null.

PMID
30865549
Full Text

Jolly, MK, Ware, KE, Xu, S, Gilja, S, Shetler, S, Yang, Y, Wang, X, Austin, RG, Runyambo, D, Hish, AJ, Bartholf DeWitt, S, George, JT, Kreulen, RT, Boss, M-K, Lazarides, AL, Kerr, DL, Gerber, DG, Sivaraj, D, Armstrong, AJ, Dewhirst, MW, Eward, WC, Levine, H, and Somarelli, JA. "E-cadherin represses anchorage-independent growth in sarcomas through both signaling and mechanical mechanisms." Molecular Cancer Research : Mcr (March 12, 2019).

PMID
30862685
Full Text

Xu, S, Ware, KE, Ding, Y, Kim, SY, Sheth, MU, Rao, S, Chan, W, Armstrong, AJ, Eward, WC, Jolly, MK, and Somarelli, JA. "An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance." Journal of Clinical Medicine 8, no. 2 (February 7, 2019).

PMID
30736412
Full Text

Labriola, MK, Batich, KA, Zhu, J, McNamara, MA, Harrison, MR, Armstrong, AJ, George, DJ, and Zhang, T. "Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma." Clinical Genitourinary Cancer (February 5, 2019). (Review)

PMID
30858035
Full Text

Jolly, MK, Somarelli, JA, Sheth, M, Biddle, A, Tripathi, SC, Armstrong, AJ, Hanash, SM, Bapat, SA, Rangarajan, A, and Levine, H. "Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas." Pharmacology & Therapeutics 194 (February 2019): 161-184. (Review)

PMID
30268772
Full Text

Zhang, T, George, DJ, and Armstrong, AJ. "Precision Medicine Approaches When Prostate Cancer Akts Up." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 25, no. 3 (February 2019): 901-903.

PMID
30206162
Full Text

Sonpavde, G, Agarwal, N, Pond, GR, Nagy, RJ, Nussenzveig, RH, Hahn, AW, Sartor, O, Gourdin, TS, Nandagopal, L, Ledet, EM, Naik, G, Armstrong, AJ, Wang, J, Bilen, MA, Gupta, S, Grivas, P, Pal, SK, Lanman, RB, Talasaz, A, and Lilly, MB. "Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer." Cancer (January 8, 2019).

PMID
30620391
Full Text

Beltran, H, Oromendia, C, Danila, DC, Montgomery, B, Hoimes, C, Szmulewitz, RZ, Vaishampayan, U, Armstrong, AJ, Stein, M, Pinski, J, Mosquera, JM, Sailer, V, Bareja, R, Romanel, A, Gumpeni, N, Sboner, A, Dardenne, E, Puca, L, Prandi, D, Rubin, MA, Scher, HI, Rickman, DS, Demichelis, F, Nanus, DM, Ballman, KV, and Tagawa, ST. "A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 25, no. 1 (January 2019): 43-51.

PMID
30232224
Full Text

Zhang, T, Armstrong, AJ, George, DJ, and Huang, J. "The promise of immunotherapy in genitourinary malignancies." Precision Clinical Medicine 1, no. 3 (December 19, 2018): 97-101.

PMID
30687563
Full Text

Armstrong, AJ, Nordle, O, and Morris, M. "Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply." Jama Oncology (December 13, 2018).

PMID
30543364
Full Text

Pages